SCHEMBL13674397

SCHEMBL13674397

CN(C(=O)OC(C)(C)C)c1ccc(CBr)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAX8 Q06710 1/20 0.49
BRD4 O60885 2/20 0.40
CREBBP Q92793 1/20 0.40
NOTUM Q6P988 1/20 0.39
LMNA P02545 2/20 0.38
NR1H4 Q96RI1 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
AKT1 P31749 1/20 0.37
NR1H3 Q13133 3/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.35
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
CHRNB2 P17787 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8018111 0.86 PAX8 (0.55) PAX8BRD4CREBBPNOTUMLMNA
SCHEMBL7531272 0.85 PAX8 (0.50) PAX8BRD4CREBBPNOTUMLMNA
SCHEMBL16197281 0.85 PAX8 (0.50) PAX8BRD4CREBBPNOTUMLMNA
SCHEMBL14090333 0.84 PAX8 (0.49) PAX8BRD4CREBBPNOTUMLMNA
SCHEMBL16856539 0.84 PAX8 (0.49) PAX8BRD4CREBBPNOTUMLMNA
SCHEMBL25960281 0.84 PAX8 (0.49) PAX8BRD4CREBBPNOTUMLMNA
SCHEMBL4615305 0.83 NR1H4 (0.56) PAX8BRD4CREBBPLMNANR1H4
SCHEMBL4015896 0.81 PAX8 (0.49) PAX8BRD4CREBBPNOTUMLMNA
SCHEMBL6959925 0.81 PAX8 (0.47) PAX8BRD4CREBBPNOTUMLMNA
SCHEMBL25960283 0.81 PAX8 (0.47) PAX8BRD4CREBBPNOTUMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 PAX8 4719/4885BRD4 3776/4885CREBBP 2060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.